Array Biopharma (ARRY) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.33 --0%
Financial Fact:
Weighted average shares outstanding - basic (in shares): 145.1M
Today's EPS Names:
ROX, KEEL, SENEA, More
Financial Fact:
Weighted average shares outstanding - basic (in shares): 145.1M
Today's EPS Names:
ROX, KEEL, SENEA, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MACOM Technology Solutions (MTSI) Tops Q4 EPS by 9c ; Offers Guidance
- Icahn Enterprises L.P. (INGR) Tops Q3 EPS by 12c ; Offers Guidance
- Privia Health Group, Inc. (PRVA) Tops Q3 EPS by 12c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
